IMDRF Tackles Confusion Over Clinical Evidence Expectations for Device Software
This article was originally published in SRA
If all goes to plan, the International Medical Device Regulators Forum will have completed by July a draft guidance that explores when and to what level clinical evaluation and evidence is necessary or acceptable to support marketing authorizations of software as a medical device (SaMD)1.
You may also be interested in...
Saudi Arabia has proposed adopting IMDRF guidelines on the regulation of medical device software. It has also issued a separate proposal to help medical device establishments comply with national regulatory requirements on the storage, handling and distribution of medtech products.
The US agency issued a draft guidance on clinical evaluation considerations for "software as a medical device." But FDA did not write the guidance internally. Instead it is an International Medical Device Regulators Forum document that was put together collaboratively by regulatory officials from across the globe. This is the first time FDA is attempting to wholesale adopt an IMDRF guidance document as its own.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).